NCT06717672

Brief Summary

  1. 1.\*Reduced opioid consumption
  2. 2.\*Decreased pain scores
  3. 3.\*Fewer opioid-related side effects
  4. 4.\*Improved patient satisfaction

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P25-P50 for phase_3 pain

Timeline
Completed

Started Nov 2023

Shorter than P25 for phase_3 pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 5, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 10, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 10, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

November 30, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 5, 2024

Completed
Last Updated

December 10, 2024

Status Verified

December 1, 2024

Enrollment Period

6 months

First QC Date

November 30, 2024

Last Update Submit

December 5, 2024

Conditions

Keywords

LidocaineOpiodsPeri-operative painDecrease Opioid requirementAmbulatory surgeries

Outcome Measures

Primary Outcomes (1)

  • Peri-operative pain

    Visual Analog pain scale to rate pain scale comprises 0 to 10 score 0 minimum to 10 Maximum

    at 2 hours, 4 hours, 6 hours

Study Arms (2)

Intervention group

ACTIVE COMPARATOR

intervention group recieve inj lidocaine

Drug: Lidocaine 2% without vessel constrictor

Control group

PLACEBO COMPARATOR

control group receive Normal saline

Drug: Normal Saline

Interventions

1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing. 2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns. 3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies.

Intervention group

Normal saline used is an iv fluid given for fluid replacement

Control group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA 1 and 2
  • patient age between 18 and 65 years
  • Patient undergoing ambulatory surgeries

You may not qualify if:

  • Pregnant women
  • Allergic to Lidocaine Patient who had fever and treated with antibiotic and steroid in last month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Liaquat National Hospital and Medical College

Karachi, Sindh, Pakistan

Location

Related Links

MeSH Terms

Conditions

PainPain, Postoperative

Interventions

LidocaineSaline Solution

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic Processes

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Hanesh Tanwani Dr Hanesh Tanwani

    Liaquat National Hospital and Medical College

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 30, 2024

First Posted

December 5, 2024

Study Start

November 5, 2023

Primary Completion

May 10, 2024

Study Completion

May 10, 2024

Last Updated

December 10, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

\*Informed consent\*: Participants may not have provided informed consent for their data to be shared, which could raise ethical concerns. Patient confidentiality\*: Sharing IPD could compromise patient confidentiality and anonymity, potentially harming participants or their families.

Locations